GlassScriptPhysician profile
Alyson B Oblock
NPI 1508414012
$3,989.85
in general payments reported to CMS, 2019-2025
28 companies · $929 in 2025
The $929 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $307 · 2023: $1,446 · 2024: $1,307 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,682.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $630.89 | 2022-2025 | |
| Pfizer INC. | $586.73 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $453.74 | 2022-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.75 | 2022-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $197.40 | 2022-2024 | Xarelto |
| Impulse Dynamics (USA) INC. | $173.76 | 2024 | Optimizer |
| Edwards Lifesciences Corporation | $172.60 | 2025 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $169.08 | 2023-2024 | Watchman Flx |
| Baxter Healthcare | $166.20 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor |
| Kiniksa Pharmaceuticals, LTD. | $163.14 | 2022-2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $127.69 | 2024 | Arcalyst |
| Novo Nordisk INC | $115.18 | 2022-2024 | Rybelsus, Ozempic |
| Esperion Therapeutics, INC. | $104.08 | 2022-2024 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $103.87 | 2023-2025 | Eliquis, Camzyos |
| Amgen INC. | $78.43 | 2023-2024 | Repatha |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $75.77 | 2024-2025 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $72.34 | 2023-2025 | Farxiga, Andexxa, Lokelma |
| Philips North America LLC | $71.12 | 2023-2024 | (Ck4) Mcot |
| Irhythm Technologies, INC. | $50.33 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Cvrx, INC. | $47.91 | 2023-2025 | Barostim Neo System |
| Abbott Laboratories | $46.42 | 2023 | Amplatzer Amulet, Mitraclip |
| Kestra Medical Technology Services, INC. | $30.99 | 2024 | Assure Wcd |
| Abbvie INC. | $28.20 | 2025 | |
| Genzyme Corporation | $24.71 | 2025 | |
| Medtronic, INC. | $24.41 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $24.06 | 2025 | Evkeeza |
| Sanofi-Aventis U.S. LLC | $23.19 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.86 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyson Oblock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.